Vivoryon Therapeutics VVY

AMS: VVY | ISIN: NL00150002Q7   31/05/2024
2,395 EUR (+19,75%)
(+19,75%)   31/05/2024

23 mei 2024 · Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease · Persbericht

15 mei 2024 · Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024 · Persbericht

8 mei 2024 · Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024 · Persbericht

24 april 2024 · Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates · Persbericht

16 april 2024 · Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024 · Persbericht

15 maart 2024 · Vivoryon Therapeutics N.V. Announces Changes to Board Composition · Persbericht

4 maart 2024 · Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease · Persbericht

8 januari 2024 · Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024 · Persbericht

6 december 2023 · Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress · Persbericht

28 november 2023 · Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023 · Persbericht

22 november 2023 · Mee m/d markt: 'Make exegese great again' · Bolero.be

In Europa (-0,14%) schommelden de aandelen dicht bij het hoogste peil van de voorbije 5 weken en half, terwijl de verhandelde volumes mak bleven in de aanloop naar de Amerikaanse Thanksgiving-vakantie op donderdag. Wat eveneens...

7 november 2023 · Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference · Persbericht

26 oktober 2023 · Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision · Persbericht

23 oktober 2023 · Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose · Persbericht

17 oktober 2023 · Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders · Persbericht

5 oktober 2023 · Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference Participation · Persbericht

15 september 2023 · Vivoryon Therapeutics N.V. Extraordinary General Meeting Approved Appointment of New Executive Directors to the Board · Persbericht

7 september 2023 · Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational Progress · Persbericht

31 augustus 2023 · Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023 · Persbericht

4 augustus 2023 · Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023 · Persbericht

Mijn selecties